1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends

Global & USA BioSimilar Market Analysis to 2021; BioBetters, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte Colony-Stimulating Factor (G-CSF), Anti-Tumor Necrosis Factor (Anti-TNF), Monoclonal Antibodies (MAbs), Insulins, Interferons, Produ

  • August 2015
  • 271 pages
  • Kelly Scientific Publications
Report ID: 3612158


Table of Contents

Biosimilars are highly-similar versions of biological drugs that are indicated for cancer, kidney disorders and a wide range of autoimmune diseases. Originator biologics are the most expensive drugs in the pharmaceutical industry and many of them cost nearly $100,000 per patient per year. These expensive biologics impose a heavy financial burden on patients and healthcare systems, limiting easy access and optimal care. Patent protection for some of the biologics has already expired and many more are to lose patent rights between now and 2020. This has given an opportunity to biotechnology companies to develop and market biosimilars with a cost benefit of about 20% to 30%.

In order to gain a slice of the $190 billion worth of biologic’s market, many biotechnology companies have ventured into the biosimilar sector bringing out less-expensive copies of reference biologics. Biosimilars have been in the E.U. market since 2006 and less-regulated markets such as China, India, and South Korea have a number of biosimilars in their domestic markets. After a long delay, finally, the FDA took a historic decision to approve the first biosimilar Zarxio from Sandoz on March 6, 2015. The coming years will witness the flooding of large number of biosimilars into the U.S., which happens to be the largest market for biopharmaceuticals.

This report provides a comprehensive overview of the size of biosimilars’ market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. On total, about 44 biosimilars are available in the global market and currently the E.U. is the major market with 19 approved biosimilars in use. A significant number of biosimilars are available in the markets of China, India, South Korea and Latin America. Biosimilars from these emerging countries are approved by a less-stringent approval pathway and therefore, the commercialization of their products is mostly confined to the domestic markets. The report describes how the long-awaited FDA approval of Zarxio from Sandoz (biosimilar for Amgen’s Neupogen) in March 2015 is to transform the otherwise nascent market. The report includes:

- An overview of biosimilars that includes differences between biologics; biosimilars and generics, definition of biosimilars by different agencies, barriers in developing biosimilars, cost of developing biosimilars.
- A summary of regulatory pathways in various geographic regions.
- Development of biosimilars in Europe, China, India, South Korea, Latin America and the sudden spurt in the development of biosimilars in the U.S.
- A list of biosimilar developers in different geographic locations.
- An overview of biobetters that includes regulatory considerations, differences between biosimilars and biobetters, various biobetters that are in developmental stages, and the companies with the largest biobetter pipeline.
- An overview of approved biosimilars in the E.U., U.S., India, South Korea and Latin America.
- The market impact of biosimilars on their reference biologics such as Epogen, Humira, Remicade, Neupogen, Neulasta, Enbrel, Rituxan, Herceptin, Avastin and Lantus through 2021.
- The top ten biologics on the focus of biosimilar developers.
- The five major classes of biologics and their biosimilar counterparts.
- The current landscape of originators of biosimilars.
- Global market for biologics by region, through 2021.
- Global market for biologics by indication, through 2021.
- Global market for biologics by drug class, through 2021.
- Global market for biosimilars by region, through 2021.
- Global market for biosimilars by indication, through 2021.
- Global market for biosimilars by drug class, through 2021.
- Profiles of 95 biosimilar developers, their products in the market and their product pipeline.
- A newsletter in the appendix gives the latest news of biosimilar sector as of February 2015.

1.3 Key Questions Answered in This Report

- How do biologics, biosimilars and generics vary from each other?
- What are the different quality, safety and efficacy assessment tests for biosimilars?
- How much is being spent for developing a biosimilar molecule?
- How many years does a biosimilar take to reach the commercial market?
- How do regulatory pathways differ from region to region?
- What is the need for biosimilars?
- What are the different platforms for the development of biosimilars?
- What is the success rate in the development of a biosimilar when compared to a biologic and generic?
- What are the most attractive target biologics for the development of biosimilars?
- How many biosimilars are being developed for Avastin, Enbrel, Herceptin, Humira, Neulasta, and Rituxan, and what are they?
- How many biosimilar MAbs are being developed and what are they?
- How much can the U.S. save by the introduction of biosimilars, through 2024?
- Which companies are involved in developing biosimilar MAbs in South Korea?
- Who are the Indian players active in Indian biosimilar industry?
- What are the biosimilar drugs being developed by the Indian biosimilar developers?
- Name the biosimilars approved in the E.U., India, South Korea and Latin America?
- What is the current utilization rate of biosimilars in the E.U. countries?
- The biosimilars approved for use in Germany, Netherlands, U.K., South Korea, Japan, Latin America and India?
- How far the markets of Epogen, Humira, Remicade, Neupogen, Neulasta, Enbrel, Rituxan, Herceptin, Avastin and Lantus will be affected by the entry of biosimilar counterparts?
- What are the top ten biologics that have become the focus of biosimilar developers?
- What are the five major classes of biologics that have attracted the attention of biosimilar developers and what are their current market shares?
- What are the top ten biologic drugs from 2009 to 2014?
- Which biologic drugs dominated the U.S. market, between 2010 and 2014?
- How much is the Medicare Part B spending on biologics in the U.S.?
- What are the top-eight biologic drugs in the E.U. market?
- How many biologics maintain absolute dominance in the German market?
- What is the average cost of a biologic drug in the U.S.?
- How did the market for biosimilars perform between 2007 and 2014?
- How small is the market for biosimilars, when compared to that of biologics?
- What favorable signs are there in the industry to hope for an accelerated growth for biosimilars?
- What is the projected global and regional market for biosimilars from 2014 to 2021?
- What is the projected market for biosimilars by major drug classes from 2014 to 2021?
- Who are the market leaders in the biosimilar sector?
- What was the market for biosimilars in the major E.U. countries between 2007 and 2013?
- How much is the competition between biologics and biosimilars in the German market between 2007 and 2020?
- What is the potential market for biosimilars in the U.S., through 2020?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Erythropoietin (EPO) Drugs Market Analysis By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application, And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • May 2017
  • by Grand View Research

The global erythropoietin (EPO) drugs market is expected to reach USD 17.4 billion by 2025, according to a new report by Grand View Research, Inc. Rising incidence of chronic diseases such as CKD and cance ...

Global Biosimilars Market

  • $ 4250
  • Industry report
  • July 2017
  • by Mordor Intelligence LLP

The global biosimilar market was estimated to be USD XX million in 2016 and is expected to reach USD XX million by 2021, witnessing a CAGR of XX% during the forecast period. Biosimilar is a biological ...

Japan Biosimilars – A start of Authorized Biosimilar Era? - Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market!

  • $ 4000
  • Industry report
  • August 2017
  • by MP Advisors

Major JP Innovator vs. Early entrant Mid size Japanese companies- TA focus approach – A Win Win Game! In this report, we attempt to evaluate key upcoming opportunity for Japan BS market, its competitive ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.